公开(公告)号：US20110237566A1

公开(公告)日：2011-09-29

申请号：US13130144

申请日：2009-11-24

申请人： Rustum S. Boyce ,  Muhammad Sofian Asi Sihombing ,  Hiroki Sone

发明人： Rustum S. Boyce ,  Muhammad Sofian Asi Sihombing ,  Hiroki Sone

IPC分类号： A61K31/553 ,  C07D313/00 ,  C07D413/14 ,  C07D405/14 ,  C07D267/10 ,  C07D243/08 ,  A61K31/336 ,  A61K31/5355 ,  A61K31/497 ,  A61K31/4523 ,  A61K31/551 ,  A61P35/00

CPC分类号： C07D407/06 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14

摘要： The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain macrolide compounds (for convenience, collectively referred to herein as “MC compounds”), which, inter alia, are useful in treatment of cancer. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to treat proliferative conditions such as cancer, and in the treatment of diseases and conditions that are mediated by the regulation (e.g. inhibition) of cell proliferation, optionally in combination with another agent.

摘要翻译： 本发明一般涉及治疗化合物的领域，更具体地涉及某些大环内酯类化合物（为方便起见，本文统称为“MC化合物”），其尤其可用于治疗癌症。 本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在体外和体内的用途，以治疗增殖性疾病如癌症，以及治疗由调节介导的疾病和病症 （例如抑制）细胞增殖，任选与另一种试剂组合。

公开(公告)号：US08019468B2

公开(公告)日：2011-09-13

申请号：US12300203

申请日：2007-04-25

申请人： Takao Hayashi ,  Hiroki Sone ,  Toyokazu Kobayashi ,  Yoshinori Yamada ,  Akiya Inoue ,  Masayuki Tsujino ,  Hiromichi Kawano

发明人： Takao Hayashi ,  Hiroki Sone ,  Toyokazu Kobayashi ,  Yoshinori Yamada ,  Akiya Inoue ,  Masayuki Tsujino ,  Hiromichi Kawano

IPC分类号： G06F19/00

CPC分类号： G06Q10/08

摘要： A transport scenario composed of a basic transport (From) from a transport starting point to, e.g., a buffer near the transport destination point and a basic transport (To) from the buffer to the transport destination point is created in response to a transport request of a production controller for transport whose loading times at the transport starting point and at the transport destination point are specified. The buffer is reserved so as to perform the basic transport (From) and the basic transport (To), transport vehicles are allocated, the travel time to the transport starting point or the buffer and the travel time from the transport starting point or the buffer are estimated, and transport instructions are given to the transport vehicles. The possibility that the loading times are out of the specified period is evaluated. If the possibility is larger, the impossibility of a just-in-time transport is notified to the production controller.

摘要翻译： 响应于传输请求创建由传输起始点到传输目的地点附近的缓冲区的基本传输（From）和从缓冲区到传输目的地点的基本传输（To）组成的传输场景 的运输起始点和运输目的地点的装载时间的运输生产控制器。 保留缓冲区以执行基本传输（From）和基本传输（To），运输车辆被分配，到运输起点或缓冲区的行驶时间以及从运送起点或缓冲区的行驶时间 并且运输指示给予运输车辆。 评估装载时间超出规定时间的可能性。 如果可能性较大，则无法及时运送即时通知生产控制员。

公开(公告)号：US07776885B2

公开(公告)日：2010-08-17

申请号：US10933629

申请日：2004-09-02

申请人： Yasuhiro Katsu ,  Satoru Iguchi ,  Hiroki Sone ,  Chikara Uchida ,  Takashi Kojima

发明人： Yasuhiro Katsu ,  Satoru Iguchi ,  Hiroki Sone ,  Chikara Uchida ,  Takashi Kojima

IPC分类号： A61K31/454 ,  C07D471/04

CPC分类号： C07D413/14 ,  C04B35/632 ,  C07D401/12 ,  C07D405/06 ,  C07D405/14

摘要： This invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and the use of such compounds for the manufacture of medicament for gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes and apnea syndrome. These compounds have 5-HT4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.

摘要翻译： 本发明提供式（I）化合物或其药学上可接受的盐，以及含有这些化合物的组合物以及这些化合物在制备胃食管反流疾病，胃肠道疾病，胃动力障碍，非溃疡的药物中的用途 消化不良，功能性消化不良，肠易激综合征（IBS），便秘，消化不良，食管炎，胃食管疾病，恶心，中枢神经系统疾病，阿尔茨海默病，认知障碍，呕吐，偏头痛，神经系统疾病，疼痛，心血管疾病，心力衰竭，心脏 心律失常，糖尿病和呼吸暂停综合征。 这些化合物具有5-HT 4受体激动活性，因此可用于治疗哺乳动物特别是人类的胃食管反流病，非溃疡性消化不良，功能性消化不良，肠易激综合征等。

公开(公告)号：US07616859B2

公开(公告)日：2009-11-10

申请号：US12155949

申请日：2008-06-12

申请人： Norihito Tokura ,  Hiroki Sone ,  Shinji Amano ,  Hisato Kato

发明人： Norihito Tokura ,  Hiroki Sone ,  Shinji Amano ,  Hisato Kato

IPC分类号： G02B6/00

CPC分类号： H01L27/0664 ,  H01L29/407 ,  H01L29/7391 ,  H01L29/7397 ,  H01L29/861

摘要： A semiconductor device includes a spaced-channel IGBT and an antiparallel diode that are formed in a same semiconductor substrate. The IGBT includes a base layer and insulated gate trenches by which the base layer is divided into a body region connected to an emitter and a floating region disconnected from the emitter. The IGBT is formed in a cell region of an IGBT region, and the diode is formed in a diode region. A boundary region of the IGBT region is located between the cell region and the diode region. A spacing between adjacent gate trenches in the boundary region is less than a spacing between adjacent gate trenches between which the floating region is located in the cell region.

摘要翻译： 半导体器件包括形成在同一半导体衬底中的间隔沟道IGBT和反并联二极管。 IGBT包括基极层和绝缘栅极沟槽，基极层被分成与发射极连接的主体区域和与发射极断开的浮动区域。 IGBT形成在IGBT区域的单元区域中，二极管形成在二极管区域中。 IGBT区域的边界区域位于单元区域和二极管区域之间。 边界区域中的相邻栅极沟槽之间的间隔小于相邻栅极沟槽之间的间隔，在该沟槽之间的浮动区域位于单元区域中。

公开(公告)号：US06469002B1

公开(公告)日：2002-10-22

申请号：US09838551

申请日：2001-04-19

申请人： Etsuo Ohshima ,  Hiroki Sone ,  Osamu Kotera ,  Rie Komatsu ,  Gregory J. LaRosa ,  Jay R. Luly

发明人： Etsuo Ohshima ,  Hiroki Sone ,  Osamu Kotera ,  Rie Komatsu ,  Gregory J. LaRosa ,  Jay R. Luly

IPC分类号： A61K31454

CPC分类号： C07D405/12 ,  C07D233/26 ,  C07D409/12

摘要： Disclosed are novel compounds and a method of treating inflammatory diseases. The method comprises administering to an individual in need an effective amount of an imidazolidine compound represented by Structural Formula (I): and physiologically or pharmaceutically acceptable salts thereof.

摘要翻译： 公开了新型化合物和治疗炎性疾病的方法。 该方法包括向需要的个体施用有效量的由结构式（I）表示的咪唑烷化合物及其生理学或药学上可接受的盐。

公开(公告)号：US08121724B2

公开(公告)日：2012-02-21

申请号：US12300025

申请日：2007-04-25

申请人： Takao Hayashi ,  Hiroki Sone ,  Toyokazu Kobayashi ,  Yoshinori Yamada ,  Akiya Inoue ,  Masayuki Tsujino ,  Hiromichi Kawano

发明人： Takao Hayashi ,  Hiroki Sone ,  Toyokazu Kobayashi ,  Yoshinori Yamada ,  Akiya Inoue ,  Masayuki Tsujino ,  Hiromichi Kawano

IPC分类号： G06F7/00 ,  G06F19/00 ,  B65G47/90 ,  G01C21/00

CPC分类号： G06Q10/06

摘要： In response to a transfer request, for which a loading time at a transfer source and a loading time at a transfer target are designated by a production controller, there is created a transfer scenario, which contains a basic transfer (From) from the transfer source to a buffer near the transfer target, for example, and a basic transfer (To) from the buffer to the transfer target. In order that the basic transfers (From, To) may be able to be executed, the buffer is reserved, and a transfer vehicle is allocated. The time period for the transfer vehicle to run to the transfer source or the buffer and the time period for the transfer vehicle to run from the transfer source or the buffer are estimated to assign a transfer command to the transfer vehicle. The possibility that the loading and the loading time may deviate from a designated period is evaluated. In case this possibility is high, a production controller is informed that a just-in-time transfer is difficult.

摘要翻译： 响应于由生产控制器指定传送源处的加载时间和传送目的地的加载时间的传送请求，创建传送场景，其包含来自传送源的基本传送（From） 到传送目标附近的缓冲器，以及从缓冲器到传送目标的基本传送（To）。 为了能够执行基本传送（From，To），保留缓冲区，并且分配传送车辆。 传送车辆运送到传送源或缓冲器的时间段以及从传送源或缓冲器运送的传送车辆的时间段被估计为向传送车辆分配传送命令。 评估装载和装载时间可能偏离指定时间段的可能性。 如果这种可能性很高，则通知生产控制器难以及时传送。

公开(公告)号：US07829971B2

公开(公告)日：2010-11-09

申请号：US12314518

申请日：2008-12-11

申请人： Hiroki Sone ,  Akira Yamada ,  Satoshi Shiraki ,  Nozomu Akagi

发明人： Hiroki Sone ,  Akira Yamada ,  Satoshi Shiraki ,  Nozomu Akagi

IPC分类号： H01L25/16 ,  H01L23/495

CPC分类号： H01L27/1203 ,  H01L23/49589 ,  H01L23/585 ,  H01L24/48 ,  H01L27/092 ,  H01L2224/48095 ,  H01L2224/48247 ,  H01L2924/00014 ,  H01L2924/1305 ,  H01L2924/13055 ,  H01L2924/13091 ,  H01L2924/14 ,  H01L2924/181 ,  H01L2924/19041 ,  H01L2924/00 ,  H01L2924/00012 ,  H01L2224/45099 ,  H01L2224/45015 ,  H01L2924/207

摘要： A semiconductor apparatus is disclosed. The semiconductor apparatus includes an SOI substrate including an active layer, a buried insulation film and a support substrate; a low potential reference circuit part located in the active layer and operable at a first reference potential; a high potential reference circuit part located in the active layer and operable at a second reference potential; a level-shifting element forming part located in the active layer and for providing a level-shift between the first and second reference potentials; and an insulation member insulating first and second portions of the support substrate from each other, wherein locations of the first and second portions respectively correspond to the low and high potential reference circuit parts.

摘要翻译： 公开了一种半导体装置。 半导体装置包括：SOI基板，包括有源层，掩埋绝缘膜和支撑基板; 位于所述有源层中并且可在第一参考电位下操作的低电位参考电路部分; 位于所述有源层中并且可在第二参考电位下操作的高电位参考电路部分; 位于有源层中的电平移动元件形成部分，用于在第一和第二参考电位之间提供电平移位; 以及绝缘构件，其将所述支撑基板的第一和第二部分彼此绝缘，其中所述第一和第二部分的位置分别对应于所述低电位和高电位参考电路部分。

公开(公告)号：US07595329B2

公开(公告)日：2009-09-29

申请号：US11153757

申请日：2005-06-14

申请人： Koji Ando ,  Satoru Iguchi ,  Noriaki Murase ,  Yoshinori Murata ,  Toyoharu Numata ,  Hiroki Sone ,  Chikara Uchida ,  Tatsuo Ueki

发明人： Koji Ando ,  Satoru Iguchi ,  Noriaki Murase ,  Yoshinori Murata ,  Toyoharu Numata ,  Hiroki Sone ,  Chikara Uchida ,  Tatsuo Ueki

IPC分类号： A61K31/445 ,  C07D401/12

CPC分类号： C07D401/12 ,  C07D211/26 ,  C07D401/06 ,  C07D401/14 ,  C07D405/06 ,  C07D405/14

摘要： This invention relates to compounds of the formula (I): wherein R1, R2, R3, A and m are each as described herein or a pharmaceutically acceptable salt or solvate thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.

摘要翻译： 本发明涉及式（I）化合物：其中R 1，R 2，R 3，A和m各自如本文所述，或其药学上可接受的盐或溶剂化物，以及含有这些化合物的组合物和这些化合物在治疗中的用途 由5-HT4受体活性介导的病症，例如但不限于胃食管反流病，胃肠道疾病，胃动力障碍，非溃疡性消化不良，功能性消化不良，肠易激综合征（IBS），便秘，消化不良，食道炎， 胃肠疾病，恶心，中枢神经系统疾病，阿尔茨海默病，认知障碍，呕吐，偏头痛，神经系统疾病，疼痛，心血管疾病如心力衰竭和心律失常，糖尿病和呼吸暂停综合征。

公开(公告)号：US20090208313A1

公开(公告)日：2009-08-20

申请号：US12300203

申请日：2007-04-25

申请人： Takao Hayashi ,  Hiroki Sone ,  Toyokazu Kobayashi ,  Yoshinori Yamada ,  Akiya Inoue ,  Masayuki Tsujino ,  Hiromichi Kawano

发明人： Takao Hayashi ,  Hiroki Sone ,  Toyokazu Kobayashi ,  Yoshinori Yamada ,  Akiya Inoue ,  Masayuki Tsujino ,  Hiromichi Kawano

IPC分类号： G05D1/02 ,  B65G69/00 ,  G06F17/00

CPC分类号： G06Q10/08

摘要： A transport scenario composed of a basic transport (From) from a transport starting point to, e.g., a buffer near the transport destination point and a basic transport (To) from the buffer to the transport destination point is created in response to a transport request of a production controller for transport whose loading times at the transport starting point and at the transport destination point are specified. The buffer is reserved so as to perform the basic transport (From) and the basic transport (To), transport vehicles are allocated, the travel time to the transport starting point or the buffer and the travel time from the transport starting point or the buffer are estimated, and transport instructions are given to the transport vehicles. The possibility that the loading times are out of the specified period is evaluated. If the possibility is larger, the impossibility of a just-in-time transport is notified to the production controller.

摘要翻译： 响应于传输请求创建由传输起始点到传输目的地点附近的缓冲区的基本传输（From）和从缓冲区到传输目的地点的基本传输（To）组成的传输场景 的运输起始点和运输目的地点的装载时间的运输生产控制器。 保留缓冲区以执行基本传输（From）和基本传输（To），运输车辆被分配，到运送起点或缓冲区的行驶时间以及从运送开始点或缓冲区的行驶时间 并且运输指示给予运输车辆。 评估装载时间超出规定时间的可能性。 如果可能性较大，则无法及时运送即时通知生产控制员。

公开(公告)号：US20050148573A1

公开(公告)日：2005-07-07

申请号：US10933629

申请日：2004-09-02

申请人： Yasuhiro Katsu ,  Satoru Iguchi ,  Hiroki Sone ,  Chikara Uchida ,  Takashi Kojima

发明人： Yasuhiro Katsu ,  Satoru Iguchi ,  Hiroki Sone ,  Chikara Uchida ,  Takashi Kojima

IPC分类号： A61K31/454 ,  A61K31/46 ,  A61P1/04 ,  C07D401/12 ,  C07D405/06 ,  C07D405/14 ,  C07D413/14 ,  C07D451/02 ,  C07D471/04 ,  C07D43/02

CPC分类号： C07D413/14 ,  C04B35/632 ,  C07D401/12 ,  C07D405/06 ,  C07D405/14

摘要： This invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and the use of such compounds for the manufacture of medicament for gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes and apnea syndrome. These compounds have 5-HT4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.

摘要翻译： 本发明提供式（I）化合物或其药学上可接受的盐，以及含有这些化合物的组合物以及这些化合物在制备胃食管反流疾病，胃肠道疾病，胃动力障碍，非溃疡的药物中的用途 消化不良，功能性消化不良，肠易激综合征（IBS），便秘，消化不良，食管炎，胃食管疾病，恶心，中枢神经系统疾病，阿尔茨海默病，认知障碍，呕吐，偏头痛，神经系统疾病，疼痛，心血管疾病，心力衰竭，心脏 心律失常，糖尿病和呼吸暂停综合征。 这些化合物具有5-HT 4受体激动活性，因此可用于治疗哺乳动物，特别是人类的胃食管反流病，非溃疡性消化不良，功能性消化不良，肠易激综合征等。